drugset / Trial / NCT00387621
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Phase 1/2
Completed
58 enrolled
Horng Chen
National Center for Research Resources (NCRR) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverTriple-blindBasic science
Summary
In congestive heart failure, cardiac output is low, blood pressure is high, and the body becomes congested with fluid. In normal people, when there is high blood pressure, the heart muscle cells secrete a hormone that excretes sodium and water in the urine, reducing blood pressure. The action of this hormone is called the natriuretic response. The purpose of this study is to determine if nesiritide can improve an impaired natriuretic response in subjects with asymptomatic systolic heart failure or asymptomatic diastolic heart failure.
Timeline
- Start
- 2006-02
- Primary completion
- 2008-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nesiritide | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |
| Subject | Nesiritide | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |